stockrowElanco Animal Health Incorporated
ELAN Healthcare Drug Manufacturers Specialty & Generic
Elanco Animal Health Incorporated’s revenue for fiscal 2025 (year ended December 2025) was $4.7 billion, up 6.22% from fiscal 2024.
- Revenue
- +10.2%
- EPS
- +450.0%
- Free cash flow
- +35.6%
- Total debt
- −6.91%
Quarter to June 2026, against a year earlier
Follow ELAN
Alert me
Elanco Animal Health Incorporated (ELAN) Net income
Elanco Animal Health Incorporated's net income for fiscal 2025 was −$232.0M, compared with $338.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$199.0M. Over the past ten years it has ranged from −$1.2B (fiscal 2023) to $338.0M (fiscal 2024); the current reading is higher than 45% of that period. Elanco Animal Health Incorporated ranks 78th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$232.0M | — |
| FY2024 | $338.0M | — |
| FY2023 | −$1.2B | — |
| FY2022 | −$78.0M | — |
| FY2021 | −$483.0M | — |
| FY2020 | −$574.0M | — |
| FY2019 | $68.0M | (21.39%) |
| FY2018 | $86.5M | — |
| FY2017 | −$310.7M | — |
| FY2016 | −$47.9M | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $54.0M | (5.26%) |
| Mar 2026 | $57.0M | — |
| Dec 2025 | −$276.0M | — |
| Sep 2025 | −$34.0M | — |
| 34 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | $702.5M |
| RDY Dr. Reddy's Laboratories Ltd compare | $273.0M |
| LNTH Lantheus Holdings, Inc. compare | $269.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $209.5M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $109.6M |
| ALKS Alkermes plc compare | −$351.0K |
| HIMS Hims & Hers Health, Inc. compare | −$142.0M |
| ELAN Elanco Animal Health Incorporated | −$199.0M |
| VTRS Viatris Inc. compare | −$607.8M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ELAN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement